Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
Viking Global Investors and related entities report beneficial ownership of 11,842,434 shares of BridgeBio Pharma, Inc. common stock, representing 6.1% of the class. This percentage is based on 193,862,871 shares outstanding as of February 12, 2026. The filing is Amendment No. 11 to a Schedule 13D and is primarily being made to remove former advisory director David C. Ott as a reporting person after his March 31, 2026 retirement, after which he is no longer a beneficial owner of the reported shares. The amendment restates the current group of reporting persons, describes their control structure, and notes that, other than transactions listed in Exhibit 99.13, no additional trades have occurred since the prior amendment.
BridgeBio Pharma submitted a New Drug Application to the FDA for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The filing is supported by the Phase 3 FORTIFY trial’s 12‑month interim analysis, which met all pre‑specified primary and secondary endpoints.
Interim data showed rapid, consistent treatment effects, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function and a favorable safety profile. BridgeBio expects, if approved, a potential U.S. launch in late 2026 or early 2027 and notes BBP-418 could become the first approved therapy for LGMD2I/R9 and potentially any form of limb-girdle muscular dystrophy.
Bridgebio Pharma Inc: The Vanguard Group amended its Schedule 13G to report 0 shares of Common Stock, representing 0% ownership. The filing notes an internal realignment effective January 12, 2026 that led Vanguard subsidiaries to report holdings separately.
Trimarchi Thomas reported acquisition or exercise transactions in this Form 4 filing.
BridgeBio Pharma, Inc. reported that its President and CFO, Thomas Trimarchi, received a grant of 59,041 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents a right to receive one share of common stock. The RSUs vest as to 1/16 of the underlying shares on May 16, 2026, and 1/16 each quarter thereafter, conditioned on his continued service. Following this grant, Trimarchi directly holds 395,626 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. reported that Chief Accounting Officer Maricel Apuli received a grant of 14,170 restricted stock units (RSUs) of common stock as equity compensation. The award was made at no cash cost to Apuli and increases her direct holdings to 136,115 shares.
The RSUs vest over time, with 1/16 of the units scheduled to vest on May 16, 2026, and 1/16 vesting each quarter thereafter until fully vested, contingent on her continued service with BridgeBio or its subsidiaries. Each RSU converts into one share of common stock upon vesting, providing long-term, service-based incentive alignment.
BridgeBio Pharma, Inc. reported that Chief Executive Officer Neil Kumar received new equity awards on March 17, 2026. He was granted stock options for 40,570 shares of common stock at an exercise price of $70.94 per share, expiring on March 16, 2036.
He also received 104,313 restricted stock units (RSUs), each representing one share of common stock. Both the option and RSU awards vest in equal 1/16 installments beginning on May 16, 2026, then quarterly, as long as he continues serving the company or its subsidiaries.
BridgeBio Pharma CEO Neil Kumar reported insider sales executed by family trusts holding company stock. On March 12–13, 2026, trusts for which he is co‑trustee sold a total of 80,000 shares of BridgeBio common stock in open‑market transactions at prices around the high‑$60s to about $70.18 per share.
After these sales, one family irrevocable trust held 635,686 shares, a revocable trust held 4,438,447 shares, and Kumar also reported 234,451 shares held directly. The transactions were carried out under a pre‑arranged Rule 10b5‑1 sales plan, and Kumar disclaimed beneficial ownership of the trust‑held shares except to the extent of any pecuniary interest.
BBIO proposes the sale of 140,000 shares of Common stock as indicated on the notice.
The filing lists multiple prior 10b5-1 sales by related parties, including recent transactions by Kumar Haldea Revocable Trust and Neil Kumar on 03/12/2026 and 02/19/2026. Examples shown include 20,000 shares sold on 03/12/2026 and 28,053 shares sold on 02/19/2026.
BridgeBio Pharma director Hannah Valantine exercised stock options to acquire 8,671 shares of common stock at $27.36 per share on March 10, 2026. She then sold the same 8,671 shares at $72.00 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she holds 7,465 shares directly and 398 shares indirectly through her spouse.
Hannah A Valantine reported a Rule 144 notice to sell Common Stock. The filing shows a planned sale tied to a 03/10/2026 stock option exercise and reports a prior sale of 25,484 shares on 02/27/2026 for $1,717,779.60.
The transaction is listed through Morgan Stanley Smith Barney LLC, with the security identified as Common and the market noted as NASDAQ. The filing is a notice of proposed resale under Rule 144 rather than a Form 3/4 insider trade report.